Barclays PLC Acquires 45,576 Shares of Celcuity Inc. (NASDAQ:CELC)

Barclays PLC lifted its holdings in shares of Celcuity Inc. (NASDAQ:CELC) by 567.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 53,605 shares of the company’s stock after purchasing an additional 45,576 shares during the period. Barclays PLC’s holdings in Celcuity were worth $800,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. nVerses Capital LLC acquired a new position in shares of Celcuity during the third quarter valued at $33,000. Prospera Private Wealth LLC acquired a new position in shares of Celcuity during the third quarter valued at $35,000. Values First Advisors Inc. acquired a new position in shares of Celcuity during the third quarter valued at $86,000. Quest Partners LLC lifted its stake in shares of Celcuity by 31.3% during the second quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after acquiring an additional 1,379 shares during the period. Finally, SG Americas Securities LLC acquired a new position in shares of Celcuity during the third quarter valued at $119,000. Institutional investors own 63.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on CELC. HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of Celcuity in a research note on Friday, November 15th. Needham & Company LLC reissued a “buy” rating and issued a $23.00 target price on shares of Celcuity in a research note on Friday, November 15th. Finally, Stifel Nicolaus increased their target price on Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Monday, October 7th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $29.17.

Celcuity Stock Performance

CELC opened at $11.23 on Thursday. The stock has a market cap of $416.97 million, a price-to-earnings ratio of -4.30 and a beta of 0.74. The business has a 50 day moving average of $12.97 and a 200-day moving average of $15.05. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. Celcuity Inc. has a 12-month low of $10.35 and a 12-month high of $22.19.

Celcuity Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.